(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 December 2019 (12.12.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/234690 A1

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 25/00* (2006.01)
A61P 11/00 (2006.01) *A61P 35/00* (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:
PCT/IB2019/054744

(22) International Filing Date:
06 June 2019 (06.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18382402.8 06 June 2018 (06.06.2018) EP

(71) Applicant: **MINORYX THERAPEUTICS S.L.** [ES/ES]; Av. Ernest Lluch 32, 08302 Mataró Barcelona (ES).

(72) Inventors: **MARTINELL PEDEMONTE, Marc**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, 08302 Mataró Barcelona (ES). **PIZCUETA LALANZA, Maria Pilar**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, 08302 Mataró Barcelona (ES). **TRAVER LOPEZ, Estefania**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, 08302 Mataró Barcelona (ES). **GARCÍA COLLAZO, Ana Maria**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, 08302 Mataró Barcelona (ES). **PÉREZ DE LA CRUZ MORENO, Maria Angeles**; Carretera del Plantio 100 2B, 28221 Majadahonda Madrid (ES).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2019/234690 A1

(54) Title: USE OF 5-[[4-[2-[5-ACETYLPYRIDIN-2-YL]ETHOXY]BENZYL]-1,3-THIAZOLIDINE-2,4-DIONE AND ITS SALTS

(57) Abstract: The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.